Cost-effectiveness analysis (CEA) is an accepted approach to evaluate cancer screening programs. CEA estimates partially depend on modeling methods and assumptions used. Understanding common practice when modeling cancer relies on complete, accessible descriptions of prior work. This review’s objective is to comprehensively examine published CEA modeling methods used to evaluate colorectal cancer (CRC) screening from an aspiring modeler’s perspective. It compares existing models, highlighting the importance of precise modeling method descriptions and essential factors when modeling CRC progression.
MEDLINE, EMBASE, Web of Science, and Scopus electronic databases were used. The Consolidated Health Economic Evaluation Reporting Standards statement and data items from previous systematic reviews formed a template to extract relevant data. Specific focus included model type, natural history, appropriate data sources, and survival analysis.
Seventy-eight studies, with 52 unique models were found. Twelve previously published models were reported in 39 studies, with 39 newly developed models. CRC progression from the onset was commonly modeled, with only 6 models not including it as a model component.
Modeling methods needed to simulate CRC progression depend on the natural history structure and research requirements. For aspiring modelers, accompanying models with clear overviews and extensive modeling assumption descriptions are beneficial. Open-source modeling would also allow model replicability and result in appropriate decisions suggested for CRC screening programs.
This systematic literature review examines how different modeling methods are used to evaluate the cost-effectiveness of colorectal cancer screening programs. Understanding these methods is important as colorectal cancer is the third most diagnosed cancer worldwide, and effective screening can significantly reduce its incidence and mortality. The review highlights that modeling methods and assumptions greatly influence the outcomes of cost-effectiveness analyses, which are crucial for healthcare decision making.
The review analyzed 78 studies, identifying 52 unique models used in cost-effectiveness analysis for colorectal cancer screening. The most common included Markov and microsimulation models, with many studies utilizing previously published models, particularly the MISCAN-Colon model. This reliance on established models is beneficial as they are often validated and calibrated with real-world data, leading to more reliable results for healthcare policy makers.
Key findings emphasize that the natural history of colorectal cancer, including its progression from polyps to cancer, should be thoroughly represented in models. This is essential for accurately assessing the healthcare resources required for screening and treatment. Additionally, the review calls for clearer descriptions of modeling assumptions to enhance transparency and reproducibility in research.
The review underscores the need for effective screening programs that utilize reliable models to ensure the best health outcomes. Healthcare decision makers are encouraged to support the development and use of models that incorporate detailed disease progression and country-specific data. Lastly, researchers are urged to improve the quality of reporting in cost-effectiveness analyses by providing comprehensive details about the methods and assumptions used.
In conclusion, advancing the methodologies of health economic evaluations can lead to better-informed decisions regarding colorectal cancer screening programs, ultimately improving patient outcomes and optimizing healthcare resources. Open-source modeling practices are recommended to foster collaboration and enhance the replicability of research findings.
Note: This content was created with assistance from artificial intelligence (AI) and has been reviewed and edited by ISPOR staff. For more information or for inquiries on ISPOR’s AI policy, click here or contact us at info@ispor.org.